This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer. It covers the use of PROMs in patients with cancer from the start of active treatment during follow-up and at the end of life. Recommendations are based on available scientific evidence and the authors’ collective expert consensus. Authorship includes a multidisciplinary group of experts from Europe, North America, Asia and Australia.
The role of patient-reported outcome measures in the continuum of cancer clinical care. ESMO Clinical Practice Guideline / Di Maio, M.; Basch, E.; Denis, F.; Fallowfield, L. J.; Ganz, P. A.; Howell, D.; Kowalski, C.; Perrone, F.; Stover, A. M.; Sundaresan, P.; Warrington, L.; Zhang, L.; Apostolidis, K.; Freeman-Daily, J.; Ripamonti, C. I.; Santini, D.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 33:9(2022), pp. 878-892. [10.1016/j.annonc.2022.04.007]
The role of patient-reported outcome measures in the continuum of cancer clinical care. ESMO Clinical Practice Guideline
Zhang, L.;Santini, D.
2022
Abstract
This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer. It covers the use of PROMs in patients with cancer from the start of active treatment during follow-up and at the end of life. Recommendations are based on available scientific evidence and the authors’ collective expert consensus. Authorship includes a multidisciplinary group of experts from Europe, North America, Asia and Australia.| File | Dimensione | Formato | |
|---|---|---|---|
|
DiMaio_Role_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
569.73 kB
Formato
Adobe PDF
|
569.73 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
